Insulet Corporation PODD
Healthcare · Medical Devices · United States · S&P 500
Based on the available data, Insulet Corporation gets an algorithmic score of 64/100. It trades at 132.84 $, with a bearish technical trend (RSI 35.7) and 44.5% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (26.0%): generates strong profit on equity.
- Sustained revenue growth (27.5% compound annual).
Weaknesses
- —
Fundamentals
| P/E | 25.02 |
| Forward P/E | 17.24 |
| PEG | 1.04 |
| P/B | 6.48 |
| EV/EBITDA | 15.65 |
| P/S | 3.02 |
| ROE % | 26.02 |
| ROA % | 9.71 |
| Gross margin % | 71.08 |
| Operating margin % | 16.18 |
| Net margin % | 12.29 |
| Revenue growth % (y/y) | 23.50 |
| Earnings growth % (y/y) | 328.60 |
| Revenue CAGR % | 27.54 |
| Earnings CAGR % | 277.32 |
| Debt/Equity % | 66.69 |
| Current ratio | 2.48 |
| FCF yield % | 3.80 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -8.5 % |
| 3 months | -12.8 % |
| 6 months | -36.1 % |
| YTD | -53.0 % |
| 1 year | -58.2 % |
| 3 years | -14.7 % |
| 5 years | -54.7 % |
Risk
| 1-year volatility | 44.5 % |
| Beta | 0.76 |
| 5-year max drawdown | -62.6 % |
| Sharpe 1A | -1.82 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.